Nikita Kostin

Mr. Nikita Kostin

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
YLYakov Lomakin
Yakov Lomakin
LOLeyla A. Ovchinnikova
Leyla A. Ovchinnikova
STStanislav S. Terekhov
Stanislav S. Terekhov
SDSamir S. Dzhelad
Samir S. Dzhelad
IYIgor Yaroshevich
Igor Yaroshevich
AGAlexander Gabibov
Alexander Gabibov
Identifying high-affinity antibodies in human serum is challenging due to extremely low number of circulating B cells specific to the desired antigens. Delays caused by a lack of information on the immunogenic proteins of viral origin hamper the development of therapeutic antibodies. We propose an efficient approach allowing for enrichment of high-affinity antibodies against pathogen proteins with simultaneous epitope mapping, even in the absence of structural information about the pathogenic immunogens. To screen therapeutic antibodies from blood of recovered donors, only pathogen transcriptome is required to design an antigen polypeptide library, representing pathogen proteins, exposed on the bacteriophage surface. We developed a two-dimensional screening approach enriching lentiviral immunoglobulin libraries from the convalescent or vaccinated donors against bacteriophage library expressing the overlapping set of polypeptides covering the spike protein of SARS-CoV-2. This platform is suitable for pathogen-specific immunoglobulin enrichment and allows high-throughput selection of therapeutic human antibodies.

29 October 2022 in Acta Naturae
Verified
Journal Article
Open access
PDF file
NKNikita Kostin
Nikita Kostin
TBT. V. Bobik
T. V. Bobik
GSG. A. Skryabin
G. A. Skryabin
MSMaria Simonova
Maria Simonova
VKV. D. Knorre
V. D. Knorre
AGAlexander Gabibov
Alexander Gabibov
Monitoring of the level of the virus-neutralizing activity of serum immunoglobulins ensures that one can reliably assess the effectiveness of any protection against the SARS-CoV-2 infection. For SARS-CoV-2, the RBD-ACE2 neutralizing activity of sera is almost equivalent to the virus-neutralizing activity of their antibodies and can be used to assess the level of SARS-CoV-2 neutralizing antibodies. We are proposing an ELISA platform for performing a quantitative analysis of SARS-CoV-2 RBD-neutralizing antibodies, as an alternative to the monitoring of the virus-neutralizing activity using pseudovirus or live virus assays. The advantage of the developed platform is that it can be adapted to newly emerging virus variants in a very short time (12 weeks) and, thereby, provide quantitative data on the activity of SARS-CoV-2 RBD-neutralizing antibodies. The developed platform can be used to (1) study herd immunity to SARS-CoV-2, (2) monitor the effectiveness of the vaccination drive (revaccination) in a population, and (3) select potential donors of immune plasma. The protective properties of the humoral immune response in hospitalized patients and outpatients, as well as after prophylaxis with the two most popular SARS-CoV-2 vaccines in Russia, were studied in detail using this platform. The highest RBD-neutralizing activity was observed in the group of hospitalized patients. The protective effect in the group of individuals vaccinated with Gam-COVID-Vac vaccine was 25% higher than that in outpatients and almost four times higher than that in individuals vaccinated with the CoviVac vaccine.

23 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYakov Lomakin
Yakov Lomakin
AKAnna Kudriaeva
Anna Kudriaeva
NKNikita Kostin
Nikita Kostin
STStanislav Terekhov
Stanislav Terekhov
AKAlena Kaminskaya
Alena Kaminskaya
ABAlexey Belogurov
Alexey Belogurov
The discovery of antibody-mediated catalysis was a breakthrough that showed antibody function is not limited to specific binding interactions, and that immunoglobulins (Igs) may also chemically transform their target antigens. Recently, so-called “natural catalytic antibodies” have been intimately linked with several pathologies, where they either protect the organism or contribute to the development of autoimmune abnormalities. Previously, we showed that myelin-reactive autoantibodies from patients with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE) exhibit the ability to recognize and hydrolyse distinct epitopes within myelin basic protein (MBP). Further, the antibody-mediated cleavage of encephalitogenic MBP peptide 81–103, flanked by two fluorescent proteins, can serve as a novel biomarker for MS. Here, we report the next generation of this biomarker, based on the antibody-mediated degradation of a novel chemically synthesized FRET substrate, comprising the fluorophore Cy5 and the quencher QXL680, interconnected by the MBP peptide 81–99: Cy5-MBP81–99-QXL680. This substrate is degraded upon incubation with either purified antibodies from MS patients but not healthy donors or purified antibodies and splenocytes from EAE but not from non-immunized mice. Data presented herein suggest the elaboration of potential specific, rapid, and sensitive diagnostic criteria of active progressive MS.

5 June 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
TBTatyana V. Bobik
Tatyana V. Bobik
NKNikita Kostin
Nikita Kostin
GSGeorge A. Skryabin
George A. Skryabin
PTPolina N. Tsabai
Polina N. Tsabai
MSMaria A. Simonova
Maria A. Simonova
AGAlexander Gabibov
Alexander Gabibov
The breastfeeding of infants by mothers who are infected with SARS-CoV-2 has become a dramatic healthcare problem. The WHO recommends that infected women should not abandon breastfeeding; however, there is still the risk of contact transmission. Convalescent donor milk may provide a defense against the aforementioned issue and can eliminate the consequences of artificial feeding. Therefore, it is vital to characterize the epitope-specific immunological landscape of human milk from women who recovered from COVID-19. We carried out a comprehensive ELISA-based analysis of blood serum and human milk from maternity patients who had recovered from COVID-19 at different trimesters of pregnancy. It was found that patients predominantly contained SARS-CoV-2 N-protein-specific immunoglobulins and had manifested the antibodies for all the antigens tested in a protein-specific and time-dependent manner. Women who recovered from COVID-19 at trimester I–II showed a noticeable decrease in the number of milk samples with sIgA specific to the N-protein, linear NTD, and RBD-SD1 epitopes, and showed an increase in samples with RBD conformation-dependent sIgA. S-antigens were found to solely induce a sIgA1 response, whereas N-protein sIgA1 and sIgA2 subclasses were involved in 100% and 33% of cases. Overall, the antibody immunological landscape of convalescent donor milk suggests that it may be a potential defense agent against COVID-19 for infants, conferring them with a passive immunity.

1 October 2018 in Fish & Shellfish Immunology
Verified
Journal Article
Closed access
NKNikita Kostin
Nikita Kostin
TBT.V. Bobik
T.V. Bobik
ESE.M. Shurdova
E.M. Shurdova
RZR.H. Ziganshin
R.H. Ziganshin
ESE.A. Surina
E.A. Surina
ISIvan V. Smirnov
Ivan V. Smirnov

1 June 2017 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
NKNikita Kostin
Nikita Kostin
NPN. A. Ponomarenko
N. A. Ponomarenko
VIV. A. Isaev
V. A. Isaev
GRG. N. Rudenskaya
G. N. Rudenskaya
TBT. V. Bobik
T. V. Bobik
ISIvan V. Smirnov
Ivan V. Smirnov